PIK3CA and neoplasm: Furthermore, patients whose tumors have PIK3CA mutations show higher response rates to PI3K/AKT/mTOR inhibitors than do patients whose tumours lack PIK3CA mutations [2], suggesting that this signaling pathway is a promising therapeutic target for this disease [3].